Login Register Cart 0
Generic placeholder image

Recent Advances in Inflammation & Allergy Drug Discovery

Editor-in-Chief

ISSN (Print): 2772-2708
ISSN (Online): 2772-2716

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Research Article

Antibacterial and Antimalarial Therapeutic Agents: A Patent Perspective

Author(s): Hai-Long Zhang* and Yongxia Li

Volume 18, Issue 1, 2024

Published on: 25 October, 2023

Page: [57 - 66] Pages: 10

DOI: 10.2174/0127722708268538231010041307

Price: $65

Abstract

Background: Antibacterial and antimalarial drugs play a critical role in combating infectious diseases. It is a continuous work to develop new types of antibacterial and antimalarial drugs.

Objective: To better understand current landscape and association of antibacterial and antimalarial agents, the European patent analysis was performed.

Methods: Antibacterial and antimalarial agents were analyzed by patent analysis. Patent documents from January 2003 to May 2022 were retrieved and analyzed.

Results: The present study indicated there were virtually three therapeutic approaches for antibacterial agents, including chemical drugs, biological products and siRNA technology. Chemical drugs were a mainstream therapeutic approach for development of both antibacterial and antimalarial agents. However, the present study found that in contrast to antimalarials, siRNA technology had been initially explored as therapeutic strategy for antibacterial agents. Also, our study is the first to show that there is a low correlation between antibacterial and antimalarial agents.

Conclusion: Globally, our study is the first one to show that it may be not a fast approach to discover antimalarial drugs from antibacterial agents based on drug repurposing. siRNA technology as therapeutic strategy had been explored and used in antibacterial field.

Keywords: Antibacterial agents, antimalarial agents, patent, patent landscape, antibacterial, antimalarial.

« Previous Next »
Graphical Abstract

[1]
Hallgren F, Lindell E, Nilsson-Helger B, Lundqvist A. Antibiotics in treatment of peritonsillar infection: clindamycin versus penicillin. J Laryngol Otol 2021; 135(1): 64-9.
[http://dx.doi.org/10.1017/S002221512100013X] [PMID: 33478601]
[2]
Gaynes R. The discovery of penicillin-new insights after more than 75 years of clinical use. Emerg Infect Dis 2017; 23(5): 849-53.
[http://dx.doi.org/10.3201/eid2305.161556]
[3]
The World Health Organization. Available from: https://www.who.int/news-room/fact-sheets/detail/malaria
[4]
The Nobel Prize organisation. Available from: https://www.nobelprize.org/prizes/medicine/2015/summary/
[5]
Klayman DL. Qinghaosu (artemisinin): An antimalarial drug from China Science (80- ) 1985; 228.
[http://dx.doi.org/10.1126/science.3887571]
[6]
Saeed-ur-Rahman , Khalid M, Kayani S-I, Jan F, Ullah A, Tang K. Biological activities of artemisinins beyond anti-malarial: A review. Trop Plant Biol 2019; 12(4): 231-43.
[http://dx.doi.org/10.1007/s12042-019-09228-0]
[7]
Maude RJ, Woodrow CJ, White LJ. Artemisinin antimalarials: preserving the “magic bullet”. Drug Dev Res 2010; 71(1): 12-9.
[http://dx.doi.org/10.1002/ddr.20344] [PMID: 21399699]
[8]
Guo Z. Artemisinin anti-malarial drugs in China. Acta Pharm Sin B 2016; 6(2): 115-24.
[http://dx.doi.org/10.1016/j.apsb.2016.01.008] [PMID: 27006895]
[9]
Meshnick SR, Thomas A, Ranz A, Xu CM, Pan HZ. Artemisinin (qinghaosu): the role of intracellular hemin in its mechanism of antimalarial action. Mol Biochem Parasitol 1991; 49(2): 181-9.
[http://dx.doi.org/10.1016/0166-6851(91)90062-B] [PMID: 1775162]
[10]
Rosenthal P, Meshnick SR. Hemoglobin catabolism and iron utilization by malaria parasites. Mol Biochem Parasitol 1996; 83(2): 131-9.
[http://dx.doi.org/10.1016/S0166-6851(96)02763-6] [PMID: 9027746]
[11]
Jacques BF-X. Neisserial vaccine compositions comprising a combination of antigens EP2255826B1, 2016.
[12]
Basil A. Alkaline compositions and their dental and medical use EP2736519B1, 2022.
[13]
Antibacterial quinoline derivatives EP2099761B1, 2008.
[14]
James M. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) EP2287306B1, 2012.
[15]
Ann-Kristin M. Malaria vaccines based on apicomplexan ferlins, ferlin-like proteins and other c2-domain containing proteins EP2507259B1, 2016.
[16]
Toshihiro H. Novel malaria vaccine EP2433645B1, 2016.
[17]
Rolf F. Novel Anti-plasmodium parasite antibodies EP2879706B1, 2017.
[18]
Thomas S. Azepanyl-derivatives and pharmaceutical compositions comprising the same with antiparasitic activity EP3164397B1, 2018.
[19]
Mary AN. Nicotinamide derivates useful as p38 inhibitors EP1474395B1, 2007.
[20]
Vennerstrom JL, Tang Y, Dong Y. Dispiro 1, 2, 4-trioxolane antimalarials EU Patent EP2203457B1, 2014.
[21]
Zhang HL, Li Y. The Patent Landscape of BRAF Target and KRAS Target. Recent Patents Anticancer Drug Discov 2023; 18(4): 495-505.
[http://dx.doi.org/10.2174/1574892818666221207091329] [PMID: 36475349]
[22]
Zhang HL, Li YX, Zhou AF, Li Y. New frontier in antiviral drugs for disorders of the respiratory system. Recent Adv Antiinfect Drug Discov 2022; 17(1): 2-12.
[http://dx.doi.org/10.2174/1574891X16666220416164740] [PMID: 35430978]
[23]
Zhang HL, Zhou AF, Li Y. Patent insight into the development of therapeutic strategies against coronaviruses. Open COVID J 2021; 1(1): 93-100.
[http://dx.doi.org/10.2174/2666958702101010093]
[24]
Bagatela BS, Lopes AP, Fonseca FLA, et al. Evaluation of antimicrobial and antimalarial activities of crude extract, fractions and 4-nerolidylcathecol from the aerial parts of Piper umbellata L. (Piperaceae). Nat Prod Res 2013; 27(23): 2202-9.
[http://dx.doi.org/10.1080/14786419.2013.821123] [PMID: 23885642]
[25]
Zhang HL, Li Y. Recent development of drugs for osteoporosis and anti-cancer agents: a patent analysis. Pharm Pat Anal 2021; 10(2): 73-82.
[http://dx.doi.org/10.4155/ppa-2021-0004] [PMID: 33844603]
[26]
The U.S. Food and Drug Administration. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-i
[27]
Gangopadhyay S, Gore KR. Advances in siRNA therapeutics and synergistic effect on siRNA activity using emerging dual ribose modifications. RNA Biol 2022; 19(1): 452-67.
[http://dx.doi.org/10.1080/15476286.2022.2052641] [PMID: 35352626]
[28]
Zhang MM, Bahal R, Rasmussen TP, Manautou JE, Zhong X. The growth of siRNA-based therapeutics: Updated clinical studies. Biochem Pharmacol 2021; 189: 114432.
[http://dx.doi.org/10.1016/j.bcp.2021.114432] [PMID: 33513339]

Rights & Permissions Print Cite
Article Metrics
14
2
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy